BioXcel Therapeutics (BTAI) Reports Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. IBM

Go back to BioXcel Therapeutics (BTAI) Reports Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501

BioXcel Therapeutics (BTAI) Misses Q1 EPS by 20c

May 12, 2020 7:11 AM EDT

BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($0.79), $0.20 worse than the analyst estimate of ($0.59).

BioXcel continued to advance on its key milestones for 2020, stated Vimal Mehta, Chief Executive Officer of BTAI. Beginning with our neuroscience program, we have made significant progress advancing BXCL501, as evidenced by our three ongoing clinical trials, SERENITY I & II and TRANQUILITY, and our Phase 1b/2 RELEASE trial initiating shortly. In parallel, we are investigating biomarkers associated with agitation in... More